Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

Pomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multiple myeloma (rrMM) in patients who often have comorbid renal conditions. To assess the impact of renal impairment on pomalidomide exposure, a population pharmacokinetics (PPK) model of pomalidomide in rrMM patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Wang, Xiaomin, O’Mara, Edward, Dimopoulos, Meletios A, Sonneveld, Pieter, Weisel, Katja C, Matous, Jeffrey, Siegel, David S, Shah, Jatin J, Kueenburg, Elisabeth, Sternas, Lars, Cavanaugh, Chloe, Zaki, Mohamed, Palmisano, Maria, Zhou, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685150/
https://www.ncbi.nlm.nih.gov/pubmed/29184451
http://dx.doi.org/10.2147/CPAA.S144606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685150/
https://www.ncbi.nlm.nih.gov/pubmed/29184451
http://dx.doi.org/10.2147/CPAA.S144606

Ejemplares similares